Merck Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MERCK, and what generic alternatives to MERCK drugs are available?
MERCK has ninety-two approved drugs.
There are twenty-six US patents protecting MERCK drugs.
There are seven hundred and thirty-five patent family members on MERCK drugs in sixty-three countries and one hundred and seventy-eight supplementary protection certificates in nineteen countries.
Summary for Merck
International Patents: | 735 |
US Patents: | 26 |
Tradenames: | 77 |
Ingredients: | 70 |
NDAs: | 92 |
Patent Litigation for Merck: | See patent lawsuits for Merck |
PTAB Cases with Merck as patent owner: | See PTAB cases with Merck as patent owner |
Drugs and US Patents for Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck | TIMOLIDE 10-25 | hydrochlorothiazide; timolol maleate | TABLET;ORAL | 018061-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck Sharp Dohme | PREVYMIS | letermovir | SOLUTION;INTRAVENOUS | 209940-002 | Nov 8, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck | ALDOMET | methyldopate hydrochloride | INJECTABLE;INJECTION | 013401-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck Kgaa | LEVOTHYROXINE SODIUM | levothyroxine sodium | TABLET;ORAL | 076752-011 | Jun 16, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck | VIOXX | rofecoxib | SUSPENSION;ORAL | 021052-002 | May 20, 1999 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck Sharp Dohme | TEMODAR | temozolomide | CAPSULE;ORAL | 021029-003 | Aug 11, 1999 | 5,260,291*PED | ⤷ Try a Trial |
Merck Sharp Dohme | DUTREBIS | lamivudine; raltegravir potassium | TABLET;ORAL | 206510-001 | Feb 6, 2015 | 7,169,780*PED | ⤷ Try a Trial |
Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-002 | Jan 26, 2001 | 5,514,650*PED | ⤷ Try a Trial |
Merck | PRINIVIL | lisinopril | TABLET;ORAL | 019558-003 | Dec 29, 1987 | 4,374,829*PED | ⤷ Try a Trial |
Merck | EMEND | aprepitant | CAPSULE;ORAL | 021549-003 | Jun 30, 2006 | 5,719,147 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MERCK drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2010-10-18 |
➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-25 |
➤ Subscribe | Injection | 115 mg/vial | ➤ Subscribe | 2012-01-25 |
➤ Subscribe | for Oral Suspension | 125 mg/Kit | ➤ Subscribe | 2016-11-23 |
➤ Subscribe | Oral Solution | 70 mg/75 mL | ➤ Subscribe | 2007-09-07 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2011-02-28 |
➤ Subscribe | Injection | 18 mg/mL, 16.7 mL vials | ➤ Subscribe | 2015-11-24 |
➤ Subscribe | Orally Disintegrating Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2006-06-21 |
➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-19 |
➤ Subscribe | Capsule | 40 mg, 80 mg and 125 mg | ➤ Subscribe | 2008-11-03 |
➤ Subscribe | Tablets | 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg | ➤ Subscribe | 2012-11-06 |
➤ Subscribe | Injection | 150 mg/vial | ➤ Subscribe | 2012-01-25 |
➤ Subscribe | For Injection | 50 mg/vial and 70 mg/vial | ➤ Subscribe | 2009-06-26 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Capsules | 140 mg and 180 mg | ➤ Subscribe | 2008-03-24 |
➤ Subscribe | Delayed-release Tablets | 100 mg | ➤ Subscribe | 2014-06-16 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2006-06-21 |
International Patents for Merck Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2008069997 | ⤷ Try a Trial |
Canada | 2800709 | ⤷ Try a Trial |
New Zealand | 721592 | ⤷ Try a Trial |
Serbia | 61609 | ⤷ Try a Trial |
Lithuania | PA2021518 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Merck Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1622880 | 300933 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LETERMOVIR; REGISTRATION NO/DATE: EU/1/17/1245 20180110 |
2576547 | PA2021518,C2576547 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: VERICIGUATAS IR JO DRUSKOS, SOLVATAI IR DRUSKU SOLVATAI ; REGISTRATION NO/DATE: EU/1/21/1561 20210716 |
0502314 | SPC/GB02/037 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
1622880 | C01622880/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: AICURIS ANTI-INFECTIVE CURES GMBH, DE |
1385870 | 410 | Finland | ⤷ Try a Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.